Roche has signed a strategic collaboration with Warp Drive Bio to discover and develop multiple new classes of antibiotics utilising the biotech’s Genome Mining™ platform in a deal worth up to US$387 M. Antibiotic resistance is a growing problem responsible for longer durations of illness, increased healthcare costs and a rising number of deaths. The deal continues Roche’s external investment in antibiotics R&D.